Galectin Therapeutics Inc GALT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.23
- Day Range
- $4.14–4.42
- 52-Week Range
- $2.03–7.13
- Bid/Ask
- $4.17 / $5.00
- Shares Outstanding
- 65.86M
- Market Cap
- $274.95M
- Volume/Avg
- 2 / 635,296
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Valuation
|
Metric
|
GALT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GALT
|
|---|---|
Quick Ratio | 1.93 |
Current Ratio | 2.15 |
Interest Coverage | −2.48 |
Quick Ratio
GALT
Profitability
|
Metric
|
GALT
|
|---|---|
Return on Assets (Normalized) | −148.97% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −788.90% |
Return on Assets
GALT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|TT&q##d | LOCK|Z#gDX | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%#CHhw% | LOCK|J%h% | $71B | |||
| argenx SE ADR
ARGX
| LOCK|^Tg!Q&t | LOCK|B?^ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l@mk#@g | LOCK|PZ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?nL!cwM | LOCK|N$q% | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^k?!^Zd | LOCK|#^<y | $26B | |||
| Moderna Inc
MRNA
| LOCK|ySF@hH | LOCK|!sF | $25B | |||
| Incyte Corp
INCY
| LOCK|@QHG#?V | LOCK|^@N | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#?&Bjz | LOCK|t$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|fWXm@@ | LOCK|K^ | $16B |
United States